Activation and Involvement of Ral GTPases in Colorectal Cancer by Martin, Timothy D. et al.
Activation and Involvement of Ral GTPases in Colorectal Cancer
Timothy D. Martin1,2, Jonathan C. Samuel1,3, Elizabeth D. Routh1, Channing J. Der1,2,*,
and Jen Jen Yeh1,2,3
1 University of North Carolina at Chapel Hill, Lineberger Comprehensive Cancer Center
2 Department of Pharmacology, Chapel Hill, NC 27599
3 Department of Surgery, Chapel Hill, NC 27599
Abstract
Current approaches to block KRAS oncogene function focus on inhibition of K-Ras downstream
effector signaling. We evaluated the anti-tumor activity of selumetinib (AZD6244,
ARRY-142886), a potent and selective MEK1/2 inhibitor, on a panel of colorectal carcinoma
(CRC) cells and found no inhibition of KRAS mutant CRC cell anchorage-independent growth.
While AKT activity was elevated in KRAS mutant cells, and PI3K inhibition did impair the growth
of MEK inhibitor-insensitive CRC cell lines, concurrent treatment with selumetinib did not
provide additional anti-tumor activity. Therefore, we speculated that inhibition of the Ral guanine
exchange factor (RalGEF) effector pathway may be a more effective approach for blocking CRC
growth. RalGEFs are activators of the related RalA and RalB small GTPases and we found
activation of both in CRC cell lines and patient tumors. Interfering RNA stable suppression of
RalA expression reduced CRC tumor cell anchorage-independent growth, but surprisingly, stable
suppression of RalB greatly enhanced soft agar colony size and formation frequency. Despite their
opposing activities, both RalA and RalB regulation of anchorage-independent growth required
interaction with RalBP1/RLIP76 and components of the exocyst complex. Interestingly, RalA
interaction with the Exo84 but not Sec5 exocyst component was necessary for supporting
anchorage-independent growth, whereas RalB interaction with Sec5 but not Exo84 was necessary
for inhibition of anchorage-independent growth. We suggest that anti-RalA-selective therapies
may provide an effective approach for KRAS mutant CRC.
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Introduction
KRAS is the most frequently mutated oncogene in colorectal cancer (CRC) (1,2) and
required for the maintenance of CRC cell growth (3–5). Therefore, it is believed that K-Ras
inhibition will provide an effective therapeutic strategy for CRC. Current strategies have
focused on inhibitors of Ras effector signaling (6). The best studied Ras effector pathways
are the Raf-MEK-ERK mitogen-activated protein kinase and phosphotidylinositol 3-kinase
(PI3K)-AKT serine/threonine protein kinase effector pathways (7), with inhibitors of
components of both pathways currently under clinical evaluation 4. Further support for the
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functional role of these effectors in cancer growth comes from the identification of
mutationally activated B-Raf (8,9) or the p110α catalytic subunit of PI3K (10) in CRC.
However, essential roles for other effectors in Ras-mediated oncogenesis have also been
demonstrated: Ral (RalGDS) and Rac (Tiam1) guanine nucleotide exchange factors and
PLCε (11–13). Tiam1 (14) or PLCε (15) deficiency impaired colon tumorigenesis in APC
mutant Min mice. Tiam1 overexpression has also been implicated in colon cancer metastatic
growth (13). These observations raise the question of whether inhibition of Raf or PI3K
effector signaling, or another effector pathway, will be the most effective approach for
treatment of KRAS mutant CRC.
Recent studies established that Ral small GTPases, activated by RalGEFs, are critical drivers
of human oncogenesis (16). Our recent studies found more frequent activation of Ral, rather
than the Raf or PI3K effector pathways, in KRAS mutant pancreatic ductal adenocarcinoma
(PDAC) tissue and cell lines (17,18). Ral has also been found to contribute to the growth of
cancer types where RAS mutations are seen infrequently (19–21).
Mutated Ras stimulates RalGEF activation, which in turn stimulates formation of the active,
Ral-GTP which then binds downstream effectors (16). One of the surprising findings
regarding Ral GTPases and cancer is the striking, sometimes opposing functions of the
otherwise highly related RalA and RalB (82% amino acid identity) proteins (19). Distinct
roles for RalA and RalB were also described for prostate (20) and bladder (21), and our
studies showed that suppression of RalA but not RalB expression impaired KRAS mutant
PDAC anchorage-independent and tumorigenic growth (18).
Less clear is the role of specific effectors in Ral-mediated oncogenesis. Perhaps the best
validated effector in tumor cell growth is the Sec5 subunit of the exocyst complex that
regulates vesicle trafficking, where Sec5 activation of the TBK1 atypical IkappaB kinase is
essential for tumor but not normal cell survival (22). The second best studied Ral effector is
RalBP1/RLIP76 that functions as a GAP for Rho small GTPases (23) and RalBP1 inhibition
suppressed tumor xenograft tumor growth in mice (24).
A key unresolved issue is which effector pathway(s) should be targeted for effective K-Ras
inhibition in CRC. We utilized pharmacologic inhibition of Raf and PI3K and found
variable effectiveness in blocking KRAS mutant CRC anchorage-independent growth. We
explored a role for Ral GTPases and found that RalA was required for CRC growth, but
surprisingly, suppression of RalB enhanced growth. Since we previously found that RalB
was dispensable for pancreatic tumor cell anchorage-independent growth, our results




CRC cell lines were obtained from ATCC and maintained in either DMEM-H or
RPMI-1640 supplemented with 10% fetal calf serum, and frozen down to maintain limited
passage history. Cell lines were treated with either selumetinib (provided by AstraZeneca) or
LY294002 for 24 h for inhibition of ERK or AKT, and soft agar analyses were done as
described previously (25), with colony formation quantitated after 14 days. Mutation status
for KRAS, BRAF and PIK3CA was derived from the COSMIC database5.
4http://clinicaltrials.gov
5http://www.sanger.ac.uk/genetics/CGP/cosmic/
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Short hairpin RNA (shRNA) sequences for human RalA or RalB were subcloned into
pSuper.retro.blast (provided by Dr. John Minna) and pSuper.retro puro (Oligoengine),
pBabe-puro retrovirus expression vectors encoding wild-type human RalA and RalB and
RNAi-insensitive Ral cDNA sequences for RalA or RalB have been described previously
(18), and were used to generate cDNA sequences encoding effector binding mutants.
shRNA sequences for human Exo84 were cloned into pSuper.retro puro and the sequences
are as follows: shExo84 1 – GGTGCCACTTTACTCTATA and shExo84 2 –
ACAATATAATTTGAATGGCTAA. RalBP1 shRNA has been described previously (42).
RNAi-insensitive RalBP1 was cloned into pBabeHAII puro with the following silent
mutations (in italics): GTAGAACGTACGATGATGT. pLKO.1 puro lentiviral vectors
encoding Sec5 shRNA (TRCN0000116102-TRCN0000116106) were obtained from
OpenBiosystems TRC shRNA library and pLKO.1 puro NS shRNA
(CAACAAGATGAAGAGCACCAA) was obtained from Sigma.
Immunoblotting
Blot analyses were done with antibodies for RalA (BD Laboratories), RalB (Millipore), β-
actin and vinculin (Sigma), GAPDH and RalBP1 (Abcam), phosphorylated ERK1 and
ERK2 T202/Y204, phospho-AKT S473, and total AKT (Cell Signaling), and total ERK1/2
(Santa Cruz Biotechnology), Exo84 (Orbigen) and Sec5 (Dr. Charles Yeaman, University of
Iowa). Activated Ral-GTP was determined by pull down analyses as described previously
(18). β-actin and vinculin blotting was done to verify equivalent total protein.
Statistical analysis
The Fisher’s exact test was used to analyze associations between two variables and the
Pearson Chi-square test was used to analyze association between more than two variables.
Results
KRAS mutant CRC cell lines are insensitive to growth inhibition by blocking MEK
Our previous studies with two MEK1/2 inhibitors, U0126 and CI-1040 (PD184352), found
that KRAS mutation status and ERK1/2 activation (pERK) did not correlate strongly with
MEK inhibitor sensitivity (26). However, both inhibitors possess off-target activities.
Therefore, we extended these analyses using a more potent and selective MEK1/2 inhibitor,
selumetinib, that is currently undergoing extensive clinical trial analyses. The majority of
previous studies evaluated MEK1/2 inhibitor activity against tumor cell lines grown as two-
dimensional anchorage-dependent cultures (27–30). When compared, it was found that
tumor cell growth in three-dimensional suspension cultures was more resistant to MEK
inhibitor treatment (31,32). Therefore, we evaluated colony formation in soft agar. Since
previous studies determined that selumetinib inhibited pERK with a half-maximal inhibition
(IC50) at a dose of <40 nM (26) or ranging from 10 to 100 nM (27), we treated cells with
one set high concentration (200 nM) to assess sensitivity, determined the degree of pERK
reduction and evaluated its effect on growth.
As we described previously (25), elevated pERK levels did not correlate with KRAS or
BRAF mutation status (Figs. 1A–C). Similar to our previous observations (25), there was
wide variation in selumetinib treatment reduction in pERK, with some cell lines showing
high sensitivity and others with relative insensitivity when evaluated in adherent cultures.
Interestingly, selumentinib treatment caused limited to no inhibition of growth in all six
KRAS mutant CRC cell lines (p=0.031) (Fig. 1D). This pattern was distinct from what we
observed with U0126 and CI-1040, where KRAS mutant SW480 growth was sensitive to
both U0126 and CI-1040 (25). Four of five BRAF mutant CRC lines were inhibited by
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selumetinib, with only NCI-H508 showing insensitivity. NCI-H508 cells were also
insensitive to U0126 and CI-1040 treatment (25). In contrast to other MEK inhibitors,
selumetinib does not exhibit inhibition of MEK5 (26,27). Nevertheless, despite inhibitor-
specific differences in sensitivity, we reached the same conclusion with all three MEK
inhibitors, that neither elevated pERK levels nor the degree of pERK inhibition was
predictive of sensitivity to selumetinib growth inhibition.
A recent study with selumetinib and CRC cell lines found an association between inhibitor
resistance and high pAKT levels (27). Therefore, we determined whether MEK inhibitor
refractory CRC cells lines corresponded to those with PIK3CA mutation and/or AKT
phosphorylation and activation (pAKT). While all five PIK3CA mutant CRC lines showed
elevated pAKT levels, elevated pAKT was also seen in PIK3CA wild type cell lines (Figs.
1A–C) and PIK3CA mutation status did not correlate with selumitinib resistance (p=0.580).
In contrast to our previous findings with KRAS mutant PDAC cell lines (25), we found
elevated pAKT in all KRAS mutant CRC cell lines, while high pAKT levels was seen in only
a subset of BRAF/KRAS WT or BRAF mutant CRC lines. High pAKT levels correlated
weakly with selumetinib insensitivity (p=0.095). Finally, we determined if three selumitinib
insensitive KRAS mutant cell lines were sensitive to PI3K inhibition. LY294002 treatment
inhibited the growth of HCT-116, SW480, and T84 cells (~50–70%). However, concurrent
treatment with both LY294002 and selumetinib did not result in further inhibitory activity
(Fig. 1E). These results suggested that the inhibition of other Ras effector pathways, either
alone or together with MEK and PI3K, may be required to effectively block the growth of
KRAS mutant CRC cells. Since we recently identified a role for a third Ras effector pathway,
leading to Ral GTPase activation, for pancreatic cancer growth (18), we focused on
validating a role for Ral GTPases in CRC growth.
RalA and RalB are activated CRC cell lines
In our analyses of KRAS mutation positive PDAC cell lines and patient tumors, we
determined that elevated steady-state levels of Ral GTPases, and not pERK or pAKT, were
associated with the majority of cell lines and tumors (17,18). Similarly, we found that ERK
activation did not correlate with the KRAS mutation status of CRC cell lines. Instead, we
determined that RalA and/or RalB are activated persistently in a majority CRC cell lines
(Fig. 2A). Similar to PDAC cell lines, Ral activation did not correlate strictly with KRAS
mutation status. Finally, we also detected activated GTP-bound RalA and RalB in CRC
patient tumors (supplementary data Fig. 1). Although across all tumor stages, there was not a
consistent difference when compared to matched normal tissue, tumors that were node
positive (98-0265, 99-0148, 99-0296) had elevated levels of RalB-GTP, total RalA, and
RalA-GTP (99-0148 and 99-0296) compared to the normal adjacent mucosa.
RalA and RalB exhibit opposing activities in regulation of CRC cell line anchorage-
independent growth
We found previously that sustained shRNA depletion of RalA but not RalB reduced PDAC
anchorage-independent growth (18). To determine if these two related isoforms also served
similar roles in CRC anchorage-independent growth, we evaluated KRAS or BRAF mutant or
KRAS/BRAF WT CRC cell lines and additionally two PDAC cell lines from our previous
study (18). Mass populations of PDAC and CRC cell lines stably-infected with each shRNA
vector were characterized by western blot analyses to verify steady-state reduction in
endogenous RalA or RalB protein (Fig. 3A and data not shown).
As we observed previously, suppression of RalA but not RalB reduced the soft agar growth
of the two PDAC cell lines (PANC-1 and T3M4; data not shown). Similarly, we found that
RalA suppression reduced colony formation efficiency of eight of eight CRC cell lines,
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independent of KRAS mutation status (Fig. 3B). Surprisingly, suppression of RalB caused a
dramatic increase in colony formation efficiency for all eight cell lines, with a two- to three-
fold increase in colonies numbers for T84 and CaCo-2 cells. A significant increase in colony
size was also seen (Fig. 4C).
RalA and RalB have been shown to have distinct functions in a number of cellular processes
or biological activities (19,33,34). However, when concurrently suppressed, the phenotype
associated with RalA is typically dominant over that of RalB (19,21,35). To address this
possibility, we extended our analyses to a total of five KRAS mutant CRC cell lines with
concurrent shRNA suppression of RalA and RalB (Fig. 4A and supplementary data Fig. 3
for LS-1034) and then evaluated colony formation in soft agar (Fig. 4B and supplementary
data Fig. 2 for LS-1034). For five of six cell lines, colony formation was similar to that of
the negative control scramble shRNA. However, for one cell line (LS174-T), concurrent
suppression caused a more significant reduction in colony formation than was seen with
suppression of RalA alone. Thus, it appears that co-depletion of RalA and RalB reverses the
RalB-depletion phenotype to a level similar to that of control shGFP.
Our observation that suppression of RalB enhanced CRC anchorage-independent growth
was unexpected, since it was reported previously that transient siRNA suppression of RalB
induced apoptosis in the SW480 CRC cell line (19) as well as in KRAS mutant lung tumor
cell lines (36). Our rationale for using sustained shRNA suppression was that we wanted to
assess the consequences of prolonged antagonism of Ral, to more accurately model the
situation that would be seen for therapeutic treatment of cancer. However, prolonged
suppression may also allow time for compensatory mechanisms to arise to offset the acute
consequences of RalB suppression. Since one compensatory mechanism may involve an
alteration in the activity of the Ral isoform that is not targeted, we determined the expression
and activation of one Ral isoform when the other isoform is suppressed by shRNA.
Surprisingly, we found that shRNA suppression of RalA was associated with a 59- to 70-
fold increase in RalB-GTP levels in the two KRAS mutant cell lines (Fig. 4D). Thus, the
reduced soft agar growth caused by RalA suppression may be mediated by the concurrent
loss of RalA function together with increased RalB activation. Conversely, suppression of
RalB in KRAS mutant cell lines was associated with a modest 1.3- to 1.5-fold increased
RalA-GTP that may contribute to the observed increased colony formation. For the BRAF
mutant HT29 cells, a converse result was seen, where RalA suppression caused only a 2.0-
fold increase in RalB-GTP formation, whereas RalB suppression caused a greater 9-fold
increase in RalA-GTP formation.
RalA and RalB both utilize RalBP1, but distinct exocyst subunits, to regulate CRC
anchorage-independent growth
The opposing activities of RalA and RalB seen in CRC anchorage-independent growth
suggests that these related isoforms may utilize different effectors in CRC cells. To address
this possibility, we utilized effector domain mutants of Ral with differential impairment in
effector binding. We first evaluated the activities of the D49E and D49N missense mutants,
which are impaired in exocyst and RalBP1/RLIP76 effector binding, respectively (37–39). It
is also possible that these mutants are defective in binding to unknown or recently described
Ral effectors such as ZONAB. Using SW480 cells, we compared the ability of ectopic
expression of WT or effector binding mutant RalA or RalB to rescue the growth effects
caused by shRNA-mediated loss of the endogenous protein (Fig. 5A and 5B). The reduced
soft agar growth caused by RalA shRNA was reversed and further enhanced by ectopic
expression of WT RalA when expressed from an shRNA-insensitive cDNA expression
vector (Fig. 5C). In contrast expression of either the D49E or D49N mutant of RalA did not
restore colony formation activity, suggesting that both the exocyst and RalBP1 contribute to
RalA promotion of CRC soft agar growth.
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We next utilized a second set of effector binding mutants, E38R and A48W (40), to assess
which exocyst component was required for RalA activity. The E38R retains the ability to
bind RalBP1 and Exo84, but not Sec5. The A48W mutant also retains the ability to bind
RalBP1 and Sec5, but is impaired in Exo84 binding. RalA E38R but not A48W expression
restored soft agar colony forming activity, indicating that Exo84 binding is important for
RalA promotion of anchorage-independent growth.
Extending these analyses to RalB, we found that RalB shRNA enhancement of soft agar
growth was reversed by ectopic expression of WT RalB expressed from an shRNA-resistant
cDNA expression vector (Fig. 5D). However, neither ectopic expression of the D49E or
D49N mutant of RalB was able to suppress soft agar colony formation activity, indicating
that both effectors are required for RalB suppression. To further delineate the role of each
exocyst component, we found that A48W but not E38R suppressed soft agar colony
formation, indicating that RalB required Sec5 binding to suppress CRC anchorage-
independent growth. Thus, RalA and RalB utilize different exocyst subunits to regulate their
opposing actions on CRC anchorage-independent growth.
Finally, to directly evaluate a role for Ral effectors in CRC growth, we stably suppressed
endogenous expression in SW480 cells (Fig. 6). As expected, since both Exo84 and RalBP1
binding were required for RalA support of anchorage-independent growth, suppression of
Exo84 and RalBP1 reduced colony formation. However, surprisingly, since Sec5 binding
was required for RalB suppression of anchorage-independent growth, Sec5 reduction
reduced, rather than enhanced, soft agar growth. This may be a consequence of Ral-
independent functions of Sec5.
Discussion
Currently, the most vigorously pursued anti-Ras approaches are inhibitors of the Raf-MEK-
ERK or PI3K-AKT effector signaling (6). However, these efforts are complicated by the
likelihood that Ras-mediated oncogenesis involves these and other effector pathways. In this
study, we extended our previous evaluation of MEK inhibitors (25) and concluded that
KRAS mutation status but not pERK activity may be a marker to define selumitinib
resistance in CRC. Although, pAKT activity was weakly associated with inhibitor
insensitivity, PIK3CA mutation status was not. We also found Ral activation in CRC cell
lines and tumors. However, in contrast to our observations in KRAS mutant PDAC, where
RalA but not RalB promoted PDAC anchorage-independent and tumorigenic growth, we
found that RalA and RalB exhibited opposing roles for CRC anchorage-independent growth.
These results reveal the striking cell context functional differences that these GTPases may
have in KRAS mutant cancers.
Our analyses with selumetinib reached the same conclusion as we did with other MEK1/2-
selective inhibitors (25); pERK activation did not reliably predict MEK inhibitor sensitivity.
However, we did find a different pattern of sensitivity to selumetinib when compared to
U0126 and CI-1040. Whereas we found previously that a subset of KRAS mutant CRC cells
did exhibit sensitivity to U0126 and CI-1040, we saw that all KRAS mutant CRC lines were
resistant to treatment with selumetinib. Perhaps this different activity reflects the more
specific nature of this MEK1/2 inhibitor and different off-target activities of the other
inhibitors (e.g., MEK5-ERK5 inhibition). Also, one potential caveat to our analyses is that
MEK inhibitory activity was determined on adherent cultures, whereas growth inhibitory
activity was determined in nonadherent three-dimensional colonies. One recent study found
that KRAS or BRAF mutation status did not correlate with selumetinib sensitivity, but did
find that inhibitor resistance correlated with weak ERK and/or strong AKT activity (27).
Consistent with their findings, we did find elevated pAKT in all KRAS mutant CRC cell
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lines and a weak association of elevated pAKT with selumitinib resistance. Although KRAS
mutant cell lines showed partial sensitivity to PI3K inhibition, we found that concurrent
PI3K inhibition did not further enhance MEK inhibitor sensitivity. Our results are consistent
with another recent study where selumetinib response did not correlate with RAS mutation or
PI3K activation (41). Our results support the need to assess the importance of other effectors
in RAS mutant cancers.
We previously observed a striking requirement for RalA but not RalB for the anchorage-
independent and tumorigenic growth of PDAC cell lines (18). In the present study, we found
that RalA was also necessary for CRC anchorage-independent growth for both KRAS and
BRAF mutant cell lines. Surprisingly, stable suppression of RalB caused a significant
enhancement of soft agar colony size and colony forming efficiency. These results extend
previous findings of striking functional differences with the related RalA and RalB isoforms
(19,21,35), and additionally reveal a significant RalB functional difference in KRAS mutant
tumor cells that arise from different tissues. While we do not have a mechanistic explanation
for this cell context difference, it may reflect differences in RalB subcellular localization or
posttranslational modifications, leading to different activation of effectors, in each tumor
type.
The different functional roles of RalA and RalB in the growth of different tumor types
complicate the issue of whether isoform-selective or pan-Ral therapeutic approaches will be
the most effective. For five of six KRAS mutant CRC cell lines, we found that concurrent
suppression of both RalA and RalB resulted in statistically insignificant reduction in colony
formation when compared to the control shGFP cells. These results contrast with previous
studies in different cancer types where the phenotype of RalA is dominant over that of RalB
(19,21,35). These observations argue that a RalA-selective therapeutic approach may be the
best approach for inhibiting the growth of CRC and PDAC cells. However, we also found
that RalB was necessary for PDAC Matrigel invasion and lung colonization metastasis (18).
Whether RalB loss will promote CRC invasion and metastasis will need to be established to
better understand the consequences of RalA and RalB ablation for tumor growth in the CRC
patient.
Our results with sustained RalB suppression differ from previous studies where transient
RalB suppression caused CRC apoptotic cell death (19,22,36). When we evaluated transient
RalB inactivation, we also observed cell death (data not shown). We suspect that with
sustained suppression of RalB, compensatory events occur to offset the initial deleterious
consequences of RalB loss. Consistent with this possibility, we observed a modest 1.3- to
1.5-fold increase in the steady-state level of RalA-GTP was increased by RalB suppression
in KRAS mutant CRC lines that may contribute to the enhancement of growth. However, we
suspect that additional more significant compensatory events must also contribute. In
contrast, we observed a 59- to 70-fold increase in RalB-GTP levels by RalA suppression in
KRAS mutant cells. Our observation that steady-state expression of constitutively activated
RalB impaired CRC growth (data not shown) argues that this increase contributes to RalA
suppression-associated growth inhibition. Since it is likely that targeted therapies focused on
signal transduction molecules will require chronic therapy to maintain persistent suppression
of target activity, we believe that our observations with sustained Ral suppression are
relevant and important for understanding the potential consequences of Ral targeted
therapies for CRC treatment.
In light of our observed opposing functions of sustained RalA and RalB depletion in CRC
anchorage-independent growth, we were surprised to find that both RalA and RalB activities
were dependent on RalBP1 binding. Since RalA and RalB exhibit different subcellular
localizations, perhaps each GTPase engages RalBP1 in spatially-distinct locations, leading
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to distinct cellular outcomes. Interestingly, suppression of RalBP1 also reduced soft agar
growth, indicating that its role in RalA function is dominant over its role in RalB function.
In any case, our implication of RalBP1 in Ral-dependent oncogenesis contrasts with other
studies where RalBP1 has not been involved. Furthermore, while both RalA and RalB
required association with exocyst components to regulate CRC growth, RalA required
association with Exo84 but not Sec5 whereas RalB required Sec5 but not Exo84 binding.
One possible explanation for this result is that the differential requirements for Sec5 and
Exo84 are unrelated to exocyst function. Certainly for Sec5, one exocyst independent
function involves the TBK1 protein kinase (22). Similarly, it was suggested that Exo84 also
exhibits an exocyst-independent function required for growth transformation (42). That
suppression of Exo84 or Sec5 expression both reduced soft agar growth may reflect both
Ral-dependent and –independent functions.
In summary, our results, while supporting the value of targeting Ral GTPases for KRAS
mutant CRC, also indicate that Ral targeted therapies may need to be tailored differently for
different cancers. For example, since we found that RalB was important for PDAC invasion
and metastasis, a RalB-selective therapy may be ideally suited for advanced PDAC. In
contrast, a RalB-selective therapy may enhance CRC tumor growth. Future studies with
genetic ablation of RalA or RalB in KRAS-driven mouse models of PDAC and CRC will
provide a more comprehensive understanding of the most effective approach for Ral
inhibition for cancer treatment.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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A–C, Steady state levels of activated pERK and pAKT, total ERK1/2 or AKT were
determined by western blot analysis in vehicle- or selumetinib-treated cells. D, Colony
forming activity was determined for vehicle- or selumetinib-treated CRC cell lines, with
activity normalized to 1.0 for vehicle-treated cultures. E, PI3K inhibition reduces the growth
of MEK inhibitor-insensitive cell lines. Mutation status for KRAS or BRAF or PIK3CA is
indicated; WT indicates no mutation for KRAS or BRAF. Data shown are representative of
two or three independent experiments.
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Activated RalA and RalB expression in CRC cell lines. Pull down analysis with GST-
RalBP1-RBD was done, followed by blot analyses with RalA-or RalB-specific antisera. Blot
analysis of total cell lysate with anti-RalA or –RalB antiserum for total Ral protein.
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RalA and RalB activity show opposing roles in regulation of CRC anchorage-independent
growth. A, Stable suppression of endogenous RalA or RalB protein expression. CRC cell
lines were stably-infected with pSuper.retro retrovirus vectors expressing shRNA for GFP
(nonspecific control), RalA or RalB. Mass populations of drug-resistant cells were
established and blot analyses were done to verify reduction in steady-state RalA or RalB
protein expression, and for vinculin to verify equivalent total protein. B, Suppression of
RalA reduces whereas suppression of RalB enhances colony formation in soft agar. Data
shown are representative of two independent experiments. The mutation status of KRAS and
BRAF is indicated with WT indicating wild type for KRAS and BRAF (COSMIC). C,
Suppression of RalB enhances colony size. Representative fields of colonies from analyses
quantitated in panel B.
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RalA activity is dominant over RalB in regulation of CRC anchorage-independent growth.
A, Stable suppression of endogenous RalA and/or RalB protein expression. CRC cell lines
were stably-infected with pSuper.retro retrovirus vectors expressing shRNA for GFP
(nonspecific control), RalA or RalB, or both RalA and RalB, and established and
characterized as described in Fig. 2A for RalA and RalB expression. B, C, Coordinate
suppression of RalA reverses the colony formation enhancement caused by RalB
suppression. (panel B) and representative fields of colonies were photographed (panel C).
Data shown are normalized to % of shGFP and are representative of two independent
experiments. D, Sustained Ral GTPase suppression is associated with increased activity of
the related Ral isoforms. CRC cell lines with stable shRNA suppression of RalA or RalB
expression were established and characterized as described in Fig. 2A. Numbers indicate the
amount of Ral-GTP/total Ral protein for RalA and RalB respectively. Data shown are
representative of two independent experiments.
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RalA and RalB require interaction with RalBP1 but distinct exocyst subunits for regulation
of anchorage-independent growth. A, RalA shRNA was used to suppress endogenous RalA
expression in SW480 cells. The cells were then infected with pBabe retrovirus vectors
encoding WT or effector binding mutant RalA proteins encoded by an shRNA-insensitive
cDNA sequence. B, RalB shRNA was used to suppress endogenous RalB expression in
SW480 cells. The cells were then infected with pBabe retrovirus vectors encoding WT or
effector binding mutant RalB proteins encoded by an shRNA-insensitive cDNA sequence.
Blot analyses were done with anti-RalA, anti-RalB and β-actin, to verify equivalent total
protein loading. C, RalA and RalB require RalBP1 and the exocyst effector interactions to
mediate their roles in CRC cell anchorage-independent growth. D, RalA requires Exo84 and
RalB requires Sec5 effector interactions to regulate CRC cell anchorage-independent
growth. Data shown are representative of two independent experiments.
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Ral effectors are required for SW480 CRC anchorage-independent growth. A, RalBP1 is
required for the anchorage-independent growth of CRC cells. RalBP1 shRNA was used to
stably suppress endogenous RalBP1 expression in SW480 cells and blot analyses were
performed with anti-RalBP1 (left panel). Numbers indicate amount of RalBP1 expression
compared to β-actin. Colony formation in soft agar was quantitated after 14 days (right
panel). The cells were then infected with pBabe retrovirus vectors encoding shRNA-
insensitive RalBP1 cDNA to verify shRNA specificity. B, Exo84 is required for SW480
anchorage-independent growth. SW480 cells were infected with nonspecific GFP shRNA or
two independent Exo84 shRNA sequences to stably suppress endogenous Exo84 expression
(left panel) and to evaluate colony formation in soft agar (right panel). C, Sec5 is required
for SW480 anchorage-independent growth. SW480 cells were infected with nonspecific
shRNA or five independent Sec5 shRNA sequences to stably suppress endogenous Sec5
expression (left panel) and to evaluate colony formation (right panel). Numbers indicate
amount of Sec5 expression compared to β-actin. Data shown are representative of two
independent experiments. E, Model for Ral in CRC anchorage-independent growth. Based
on Ral effector binding mutant analyses only, since the shRNA suppression analyses of
effector expression may be complicated by Ral-independent functions.
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